Patent ID: 7704962

Claim:
A method of inhibiting a Bcl-2-associated tumor comprising: a) obtaining a composition comprising an antisense oligonucleotide that is complementary to a Bcl-2 oligonucleotide wherein the antisense oligonucleotide comprises the sequence 5′ CGCCATCCT 3 (SEQ ID NO:4) or the sequence 5′ ATCCTTCCC 3′ (SEQ ID NO:5), combined with a substantially uncharged lipid component and a pharmaceutically acceptable carrier, wherein the lipid component comprises a neutral lipid, or a mixture of lipids, to provide the substantially uncharged lipid component; and c) administering said composition to a cancer cell, wherein said cancer cell is in a human and wherein said mixture is delivered to said human in an amount of from about 5 to about 30 mg oligonucleotide per m 2 .